Document Classification

Section Type: METHODS

Text: Subjects entered a 30-week trial, of which phases I-III were open : phase I (wk 0-6) baseline ; phase II (wk 7-9) stepwise transition to haloperidol (HAL), 30 mg/d, plus benztropine (BT), 4 mg/d ; phase III (wk 10-15) HAL, 40-60 mg/d, plus BT, 4-6 mg/d ; phase IV (wk 16-20) stepwise transition to LMP or CPZ (500 mg/d) following randomization ; phase V (wk 21-28) stepwise increase of LMP or CPZ (600-1000 mg/d, dose reduction permitted) to establish optimum dose ; and phase VI (wk 29-30) optimized dose maintained.